Apogee Therapeutics, Inc. APGE Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$74.11M-33.9% | -$69.39M-3.2% | -$65.02M-32.6% | -$66.1M-95.5% | -$55.34M-72.4% | ||
| $408K+97.1% | $406K+434% | $400K+733% | $400K+1,011% | $207K+614% | ||
| $17.16M+54.2% | $11.93M+56.8% | $11.88M+103% | $11.34M+99.1% | $11.13M+166% | ||
| $16K-98.8% | $845K+174% | -$5.3M-60.1% | $3.23M+164% | $1.37M-36.4% | ||
| $4.67M+77.0% | -$6.41M— | $7.74M-23.5% | -$5.04M-374% | $2.64M+251% | ||
| -$155K-102% | $0— | $181K+293% | $1.52M+2,166% | $6.84M— | ||
| -$802K+20.9% | -$1M-225% | -$992K-333% | -$971K-298% | -$1.01M-286% | ||
| -$55.57M-14.6% | -$62.69M+7.4% | -$54.26M-27.6% | -$62.03M-112% | -$48.48M-53.2% | ||
| —— | $62K— | $0-100% | $768K+1,406% | $4.32M+1,130% | ||
| -$35.35M-372% | -$288.63M— | $17.95M+112% | $78.13M+153% | $12.98M+125% | ||
| $378.17M— | —— | $0— | $0— | $0-100% | ||
| $411.17M+66,004% | $374.95M+745% | $19.74M+5,054% | $1.18M— | $622K-99.9% | ||
| $320.25M+1,018% | —— | -$16.57M— | —— | -$34.87M-109% | ||
| $408K+97.1% | $406K+434% | $400K+733% | $400K+1,011% | $207K+614% | ||
| -$802K+20.9% | -$1M-225% | -$992K-333% | -$971K-298% | -$1.01M-286% | ||
| $2.49M+378% | —— | $2.11M-25.0% | $2.54M+109% | -$895K-161% | ||
| $1.55M-34.9% | $1.74M-41.7% | $1.62M-53.8% | $1.76M-42.1% | $2.38M-12.2% | ||
| $980K+14.4% | $959K+26.0% | $940K+143% | $921K+229% | $857K+222% | ||
| —— | $81.01M-28.0% | $81.01M-28.0% | $81.01M-28.0% | $81.01M-28.0% | ||
| —— | $16.4M+50.7% | $16.4M+50.7% | $16.4M+50.7% | $16.4M+50.7% | ||
| $28.93M— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $229K— | ||
| -$802K+20.9% | -$1M-225% | -$992K-333% | -$971K-298% | -$1.01M-286% | ||
| —— | —— | —— | —— | $999K— | ||
| $256K— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $728K+1,868% | —— | —— | —— | $37K-93.2% | ||
| —— | -$62.75M+7.3% | -$54.26M-25.4% | -$62.8M-114% | -$52.79M-65.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Apogee Therapeutics, Inc. generate?
- Apogee Therapeutics, Inc. (APGE) generated -$234.5M in operating cash flow over the trailing twelve months.
- What is Apogee Therapeutics, Inc.'s free cash flow?
- After $5.1M of capital expenditures, Apogee Therapeutics, Inc.'s free cash flow was -$232.6M over the trailing twelve months, down 35.0% year over year.
- Where does Apogee Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Apogee Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.